Table 1.
Demographic and clinical characteristics of 2909 recent-onset Parkinson's disease cases
| Variable | Result |
|---|---|
| Age | 67.5 (9.3) |
| Male sex | 1898 (65.3%) |
| Disease duration (years) | 1.3 (0.9) |
| UPDRS 3 | 24.2 (12.1) |
| Motor subtype | |
| TD | 1303 (48.1%) |
| PIGD | 1061 (39.2%) |
| Indeterminate | 344 (12.7%) |
| MoCA | |
| Total score | 25.1 (3.5) |
| Normal | 1972 (72.1%) |
| MCI | 370 (13.5%) |
| Dementia | 394 (14.4%) |
| Antiparkinsonian medication | |
| Drug naïve | 314 (10.8%) |
| Levodopa | 1776 (61.2%) |
| Dopamine agonist | 873 (30.0%) |
| MAOB inhibitor | 723 (24.9%) |
| COMT inhibitor | 67 (2.3%) |
| Anticholinergic | 38 (1.3%) |
| Amantadine | 28 (1.0%) |
| LEDD | 292 (214) |
Data are mean (SD) or number (percentage).
COMT, catechol-O-methyl transferase; LEDD, levodopa equivalent daily dose; MAOB, monoamine oxidase type B; MCI, mild cognitive impairment; MoCA, Montreal cognitive assessment; PIGD, postural instability gait difficulty; TD, tremor dominant; UPDRS 3, Movement Disorder Society unified Parkinson's disease rating scale part 3.